Search

Your search keyword '"Rygiel, Andrew Lawrence"' showing total 7 results
Start Over Author "Rygiel, Andrew Lawrence"
7 results on '"Rygiel, Andrew Lawrence"'

1. Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Pisick, Evan P., primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Yang, Eddy Shih-Hsin, additional, Dib, Elie G., additional, Burgess, Earle Frederick, additional, Zakem, Michael Howard, additional, Rohatgi, Nitin, additional, Bilen, Mehmet Asim, additional, Warren, Sasha L., additional, Anderson, Sarah T., additional, Rygiel, Andrew Lawrence, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

2. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Ahn, Eugene R, primary, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Mangat, Pam K., additional, Calfa, Carmen Julia, additional, Alva, Ajjai Shivaram, additional, Suhag, Vijay S., additional, Hamid, Omid, additional, Dotan, Efrat, additional, Yang, Eddy Shih-Hsin, additional, Alese, Olatunji B., additional, Yost, Kathleen J, additional, Marr, Alissa S., additional, Palmer, Martin Clive, additional, Thompson, Forrest L., additional, Rygiel, Andrew Lawrence, additional, Anderson, Sarah T., additional, Islam, Samiha, additional, and Schilsky, Richard L., additional

Published
2020
Full Text
View/download PDF

3. Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Author

Al Baghdadi, Tareq, primary, Halabi, Susan, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Ahn, Eugene R., additional, Sahai, Vaibhav, additional, Alvarez, Ricardo H., additional, Kim, Edward S., additional, Yost, Kathleen J., additional, Rygiel, Andrew Lawrence, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

4. Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Alva, Ajjai Shivaram, primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Alvarez, Ricardo H., additional, Calfa, Carmen Julia, additional, Khalil, Maged F., additional, Ahn, Eugene R, additional, Cannon, Timothy Lewis, additional, Crilley, Pamela A., additional, Fisher, Julie Gottlieb, additional, Haslem, Derrick S., additional, Shrestha, Sagun, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Warren, Sasha L., additional, Rygiel, Andrew Lawrence, additional, Ranasinghe, Shamika, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

5. Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Author

Ahn, Eugene R, primary, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Halabi, Susan, additional, Dib, Elie G., additional, Haggstrom, Daniel Ernest, additional, Alguire, Kathryn B., additional, Alvarez, Ricardo H., additional, Calfa, Carmen Julia, additional, Cannon, Timothy Lewis, additional, Crilley, Pamela A., additional, Gaba, Anu G., additional, Marr, Alissa S., additional, Sangal, Ashish, additional, Thota, Ramya, additional, Antonelli, Kaitlyn R., additional, Islam, Samiha, additional, Rygiel, Andrew Lawrence, additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

6. Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Author

Al Baghdadi, Tareq, primary, Halabi, Susan, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Ahn, Eugene R, additional, Sahai, Vaibhav, additional, Alvarez, Ricardo H., additional, Kim, Edward S., additional, Yost, Kathleen J, additional, Guo, Kuo, additional, Rygiel, Andrew Lawrence, additional, Antonelli, Kaitlyn R., additional, Butler, Nicole L., additional, Bruinooge, Suanna S., additional, and Schilsky, Richard L., additional

Published
2018
Full Text
View/download PDF

7. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Al Baghdadi, Tareq, Halabi, Susan, Garrett-Mayer, Elizabeth, Mangat, Pam K., Ahn, Eugene R., Sahai, Vaibhav, Alvarez, Ricardo H., Kim, Edward S., Yost, Kathleen J., Rygiel, Andrew Lawrence, Antonelli, Kaitlyn R., Butler, Nicole L., Bruinooge, Suanna S., and Schilsky, Richard L.

Subjects
PANCREATIC cancer, PROGRESSION-free survival, TARGETED drug delivery
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known as drug targets. In this article, data from two cohorts of patients with pancreatic and biliary cancers with CDKN2A loss or mutation treated with palbociclib are reported. METHODS: Eligible patients age 12 years and older with advanced measurable or evaluable solid tumors are provided treatment according to protocol-specified genomic matching rules. The primary study end point is objective response or stable disease of at least 16 weeks duration. For each cohort, a Simon two-stage design was used with a futility evaluation after 10 patients. Secondary end points include safety, progression-free survival (PFS), and overall survival (OS). RESULTS: Between July 2016 and November 2017, 12 and 10 patients with pancreatic and biliary cancer, respectively, with CDKN2A loss or mutation were treated with palbociclib. Twenty evaluable patients (10 per cohort) were included in the analysis. No patients had objective response or stable disease at 16 weeks, and both cohorts were closed. Two patients, neither with response, were determined to be ineligible. All patients were evaluated for safety, PFS, and OS. A median PFS of 7.2 weeks (90% CI, 4.0 to 8.0 weeks) and median OS of 12.4 weeks (90% CI, 4.7 to 23.1 weeks) were observed in the pancreatic cohort. A median PFS of 7.3 weeks (90% CI, 3.9 to 7.9 weeks) and median OS of 11.1 weeks (90% CI, 5.1 to 14.0 weeks) were observed in the biliary cohort. No unexpected toxicities were observed. CONCLUSION: Palbociclib monotherapy does not have clinical activity in patients with advanced pancreatic or biliary cancers with CDKN2A loss or mutation. Toxicity is similar to reported experience with palbociclib in other tumor types. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results